BiotechTube

Methylene Blue MMX® + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer

Trial Timeline

Sep 1, 2013 → Oct 1, 2016

NCT ID
NCT01694966

About Methylene Blue MMX® + Placebo

Methylene Blue MMX® + Placebo is a phase 3 stage product being developed by Cosmo for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01694966. Target conditions include Colorectal Cancer.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Cancer were approved

Approved (15) Terminated (3) Active (4)
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved
✅5-FU based doublet chemotherapy + bevacizumabRocheApproved
✅capecitabine [Xeloda]RocheApproved
✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved
✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved
✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01694966Phase 3Completed

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
ALIMTA + OxaliplatinEli LillyPhase 2
35
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
38
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
38
CPT-11 based regimensDaiichi SankyoPre-clinical
26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
35
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
CS-1008 + irinotecanDaiichi SankyoPhase 2
27
CS-7017 + PlaceboDaiichi SankyoPhase 2
27
Patritumab DeruxtecanDaiichi SankyoPhase 2
27
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
29
DS-8273a + nivolumabDaiichi SankyoPhase 1
21